Abstract:Objective To investigate the etiology of early-onset Alzheimer disease which caused by presenilin 1 (PSEN1) mutation in one case of early-onset Alzheimer disease patient with initial symptom of epilepsy childhood and his large family. Methods From November 28, 2014 to November 14, 2015, one case of patient with initial symptom of epilepsy from age of 12 years old who was diagnosed as early-onset Alzheimer disease (the proband) in Department of Neurology of Peking University First Hospital and his large family genealogy (Ⅰ-Ⅳ generations)were recruited as research objects. Diagnostic criteria of Alzheimer disease were as follows. ①Age of onset less than 65 years old. ②The clinical examination evidence supported the diagnosis for dementia; ③Cognitive impairment showed in more than two fields. ④The progressive decline of memory and with other cognitive disorders. ⑤Without disturbance of consciousness. ⑥Without other systemic diseases and the memory and cognitive impairment which can be explained by the brain diseases. The proband, a male, 36 years old had seizures from the age of 12-year-old. He visited the hospital to seek for etiological and to study for his abnormal family history. Clinical data and genomic DNA of the proband and his family members were collected. Targeted next-generation sequencing (TGS) was performed to detect the PSEN1 mutation in the proband. All exons and exon-intron boundaries of PSEN1 were checked by polymerase chain reaction (PCR). Sanger sequencing was used to verify the corresponding mutation. The procedure of this study was consistent with ethical standard established by the committee of investigation in human beings of Peking University First Hospital. And it was approved by this committee. Informed consent was obtained from all participants. Results ①The proband (Ⅲ16) presented with seizures when he was 12 years old. After treated by sodium valproate from the age of 15 years old, the seizure was not observed. He had normal psychomotor development. His cranial MRI showed no abnormality. Relapse occurred when he stopped the drug at the age of 33 years old and sodium valproate remained effective. Primary epilepsy was suspected. However, he have presented with memory loss and disorientation since the age of 35 years old. ②His grandmother (Ⅰ2) had psychiatric disorder in her thirties and died at around 40 years old. His father (Ⅱ6), two aunts(Ⅱ4and Ⅱ5)and two uncles(Ⅱ2and Ⅱ3) presented with similar symptoms, progressive memory loss and mental retroversion at the age of about 35 years old, died in their forties, indicating early-onset Alzheimer disease. ③The sequencing results showed that, in exon 5 of PSEN1of the proband, a reported heterozygous mutation (c.346G>A, p. Glu116Lys) was identified. The same heterozygous mutation was found respectively in his son, a son (Ⅲ11,45 years old) and a grandson (Ⅳ11,7 years old) of a paternal aunt, and a daughter (Ⅲ15,29 years old) of another paternal aunt. The son of the paternal aunt who had the same mutation with the proband was 45 years old without any symptoms. Conclusions Clinical and molecular genetic features of the proband′s pedigree were clearly definite. The results confirmed the diagnosis of early-onset Alzheimer disease. It will be helpful for the genetic counseling and the prenatal diagnosis of the next generation of the family. Key words: Alzheimer disease; Presenilin-1; Epilepsy; Memory disorders; Mental retroversion; DNA mutational analysis; Familial genetic disease

Neuropathology of patients with preclinical or early clinical Alzheimer's disease with pathogenic PSEN1_p. L392V: Comparison of advanced siblings

A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism

The identification of PSEN1 p.Tyr159Ser mutation in a non-canonic early-onset Alzheimer's disease family

The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestations

Identification of a Rare <i>PSEN1</i> Mutation (Thr119Ile) in Late-Onset Alzheimer's Disease With Early Presentation of Behavioral Disturbance

Clinical and Genetic Analysis of Early-Onset Alzheimer's Disease in Two Chinese Han Families with Presenilin-1 Mutations

A Patient with Initial Symptom of Epilepsy from Age of 12 Years Old Due to Early-Onset Alzheimer Disease Caused by Presenilin 1 Mutation

P3-395: Mean Age-of-onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased Aβ42 and Decreased Aβ40

A Pathogenic Variant p.Phe177Val in PSEN1 Causes Early-Onset Alzheimer’s Disease in a Chinese Family

Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology

A New Presenilin 1 (Psen1) Mutation (p.Cys263Trp) as a Cause of Both Early and Late-Onset Alzheimer's Disease in a Large Italian Family

Mean Age-Of-Onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased A Beta 42 and Decreased A Beta 40

Clinical, Histopathological and Genetic Studies in A Family with Fatal Familial Insomnia

Patient with PSEN1 Glu318Gly and Other Possible Disease Risk Mutations, Diagnosed with Early Onset Alzheimer's Disease

Mutation Analysis of Presenilin-1 Gene in Alzheimer' S Disease Patients and the Effects of Its Mutation on Expression of Presenilin-1 and Amyloid Precursor Protein

Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage

Clinical And Neuroimaging Characterization Of Chinese Dementia Patients With Psen1 And Psen2 Mutations

PSEN2 Mutations May Mimic Frontotemporal Dementia: Two New Case Reports and a Review

Location of pathogenic variants in PSEN1 impacts progression of cognitive, clinical, and neurodegenerative measures in autosomal‐dominant Alzheimer's disease

A Novel Presenilin 1 Mutation (F388L) Identified in a Chinese Family with Early-Onset Alzheimer's Disease.

Genetic Influences on White Matter and Metabolism Abnormal Change in Alzheimer's Disease: Meta-analysis for Neuroimaging Research on Presenilin 1 Mutation